Sorrento Therapeutics' Slow-But-Steady Approach to COVID-19

Brian Orelli, PhD, The Motley Fool
·4-min read

Ji thinks the company's neutralizing antibodies are potentially more active than the frontrunners, which could help the biotech catch up and compete. Brian Orelli: We talked about a lot of different products. Henry Ji: Brian, our company has a lot of expertise, especially the antibodies space.